CN101455683A - Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof - Google Patents
Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof Download PDFInfo
- Publication number
- CN101455683A CN101455683A CNA2009100736014A CN200910073601A CN101455683A CN 101455683 A CN101455683 A CN 101455683A CN A2009100736014 A CNA2009100736014 A CN A2009100736014A CN 200910073601 A CN200910073601 A CN 200910073601A CN 101455683 A CN101455683 A CN 101455683A
- Authority
- CN
- China
- Prior art keywords
- agent
- sodium
- medicinal liquid
- liquid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a pearl clear-sighted eye drop having no bacteriostat and preparation method thereof. The pearl clear-sighted eye drop consists of pearl solution, borneol, isotonic agent, pH regulator, stabilizer, thickener, solubilizer, and so on. The preparation method uses aseptic filling technology or hot-pressing sterilizing technology. The inventive eye drop is individually packed with single dose for using once so as to assure that the production is aseptic and make the production safer, more reliable, convenient and sanitary.
Description
Technical field
The invention belongs to pharmaceutical field, particularly ZHENZHU MINGMU DIYANYE of bacteriostatic agent and preparation method thereof not.
Background technology
ZHENZHU MINGMU DIYANYE is mainly used in symptoms such as asthenopia and chronic conjunctivitis, also is used to improve diseases such as ophthalmic bloated, ophthalmic pruritus.The ZHENZHU MINGMU DIYANYE of having gone on the market all contains antibacterial, is multiple-unit container, is repeatedly used.Preparation is in case behind the Kaifeng, easily use and the preservation process in by tear and airborne microbial contamination, and then produce safety hidden danger.For prevent ophthalmic preparation behind Kaifeng in the repeated use process by the microorganism secondary pollution, all added antibacterial (preservative) in the ophthalmic preparation, all used antibacterial in the nearly all eye drop prescription in " Chinese Hospitals preparation standard ".Antibacterial claims antiseptic or preservative agent again, is meant to suppress pathogenic microorganism growth and the chemical drugs of breeding, and its primary application in pharmacy practice is exactly the microbial contamination that prevents medicine.
Though antibacterial is preventing aspect the microbial contamination certain positive effect is arranged, the untoward reaction of antibacterial also progressively is familiar with by people.It is reported antibacterial existence to the superficial cell of eye can produce zest (list of references: Liu Aiming, Li Wei, Wang Benmin, " the eye table infringement of antibacterial in the ophthalmic preparation " Chinese Hospitals pharmaceutical journal, 2002,22 (6), 371-373).The antibacterial composition can directly influence the composition of tear in the eye drop, change the microenvironment of eyeball surface, make close-connected epithelial cell structural damage originally, exfoliation of corneal epithelium, damaged, epithelial erosion appear in severe patient, corneal ulcer can take place, even corneal solution, perforation, blind.The problem that causes by antibacterial abuse more and more receive publicity (list of references: Ning Lili, " should pay close attention to the reasonable use and the quality control of antibacterial in the ophthalmic preparation R﹠D process " Chinese Hospitals pharmaceutical journal, 2007,42 (23), 1836-1838).Especially for the frequent eye drop that uses of needs, its potential danger is bigger.
Summary of the invention
The technical problem to be solved in the present invention provides ZHENZHU MINGMU DIYANYE of a kind of not bacteriostatic agent and preparation method thereof, it can avoid the secondary pollution of microorganism in using the eye drop process, also can avoid toxic and side effects and the potential risk that antibacterial causes eyes in the prior art simultaneously.
For solving the problems of the prior art, the present invention is achieved by the following technical solutions:
The present invention is the ZHENZHU MINGMU DIYANYE of bacteriostatic agent not, and it comprises following component:
Margarita liquid 18.0～22.0mL
Borneolum Syntheticum 0.9～1.1g
Isotonic agent 0.1～50g
Add the injection water and be settled to 1000mL
6 described Margarita liquids and Borneolum Syntheticum are the medicinal active ingredient of ZHENZHU MINGMU DIYANYE.
Described Margarita liquid can be according to existing production method preparation of producing Margarita liquid in " ZHENZHU MINGMU DIYANYE "; But also reference literature method preparation (as list of references: Zheng Beam unit, Chen Jian, " ZHENZHU MINGMU DIYANYE and preparation method thereof " Chinese patent application numbers 200410067013.7).
Described isotonic agent is that in sodium chloride, potassium chloride, boric acid, Borax, sodium sulfate, potassium sulfate, Chile saltpeter, potassium nitrate, sodium acetate, mannitol, glycerol, propylene glycol, the glucose one or more are composite.
The effect of isotonic agent is to equate with the osmotic pressure of tear or approaching for the osmotic pressure that makes eye drop, to reduce the zest of eye drop, improves drug effect.
The ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent, it also comprises one or more assembly in pH regulator agent, stabilizing agent, thickening agent, the solubilizing agent:
Described pH regulator agent is: 0.1～50g
Described stabilizing agent is: 0.01～5g
Described thickening agent is: 0.01～10g
Described solubilizing agent is: 1.0～10g
Described pH regulator agent is that in sodium dihydrogen phosphate, sodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, boric acid, Borax, acetic acid, sodium acetate, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, hydrochloric acid, the phosphoric acid one or more are composite.
The effect of pH regulator agent is to equate with the acid-base value of tear or approaching for the acid-base value that makes eye drop, reducing the zest of eye drop, and makes medicine stable, improves drug effect.The ZHENZHU MINGMU DIYANYE pH scope of described not bacteriostatic agent is: 4.5～7.0.
Described stabilizing agent is that in sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium nitrite, sodium thiosulfate, ascorbic acid (vitamin C), thiourea, ascorbyl stearate, dibutyl hydroxy toluene, cysteine, tocopherol acetas, dichloro isocyanide, disodiumedetate (EDTA-2Na, disodium edetate), calcio-disodium edetate, dimercaptopropanol, BAL, glycerol, mannitol, the butylated hydroxyanisol one or more are composite.
Function of stabilizer is in order to increase the stability of eye drop, to improve drug effect.
Described thickening agent is that in hyaluronate sodium, chondroitin sulfate, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, cellulose, polyvidone, polyvinylpyrrolidone, polyvinyl alcohol, chitosan, beta cyclodextrin, carbomer, glucosamine polymer, glycerol, propylene glycol, Polyethylene Glycol, the polyvinyl alcohol one or more are composite.
But the time that the thickening agent prolong drug stops within the eye can reduce simultaneously the zest to eye, improves drug effect.
Described solubilizing agent is that in ethanol, tween, glycerol, propylene glycol, the Polyethylene Glycol one or more are composite.
The effect of solubilizing agent is to increase the dissolubility of Borneolum Syntheticum in water.
The preparation method of the ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent, it may further comprise the steps:
A. precision is measured Margarita liquid 18.0～22.0mL, precision takes by weighing Borneolum Syntheticum 0.9～1.1g, isotonic agent 0.1～50g, pH regulator agent 0.1～50g, stabilizing agent 0.01～5g, solubilizing agent 1.0～10.0g, 1/5～1/4 dissolving that adds the water for injection total amount, mix, transfer the pH scope to be: 4.5～7.0, be settled to 1000mL with water for injection, get medicinal liquid.
B. under hundred grades of environment, with step a gained medicinal liquid through 0.22～0.45 μ m filtering with microporous membrane 1 to 5 time.
C. medicinal liquid detect qualified after, under hundred grades of environment, liquid drug is sealed to the unit dose package container, gets product.Said method is called sterile working's filling process.
In above-mentioned steps b process, also can at first use 0.45 μ m filtering with microporous membrane, make clarity qualified after, re-use 0.22 μ m filtering with microporous membrane, also can suitably increase the filtration number of times according to practical condition.The ZHENZHU MINGMU DIYANYE of not bacteriostatic agent of the present invention should meet that " Chinese pharmacopoeia is to the requirement under the eye drop item.
Preferably, the preparation method of the ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent, it may further comprise the steps:
A. precision is measured Margarita liquid 18.0～22.0mL, precision takes by weighing Borneolum Syntheticum 0.9～1.1g, isotonic agent 0.1～50g, pH regulator agent 0.1～50g, stabilizing agent 0.01～5g, solubilizing agent 1.0～10.0g, 1/5～1/4 dissolving that adds the water for injection total amount, mix, transfer the pH scope to be: 4.5～7.0, be settled to 1000mL with water for injection, get medicinal liquid.
B. under hundred grades of environment, with step a gained medicinal liquid through 0.22～0.45 μ m filtering with microporous membrane 1 to 5 time.
C. with step b gained medicinal liquid pressure sterilizing.
D. testing sequence c gained medicinal liquid, qualified after, under hundred grades of environment, liquid drug is sealed to the unit dose package container, gets product.Said method claims pressure sterilizing technology.
In step c, should be according to " the desired condition of Chinese pharmacopoeia sterilizing methods guarantees that aseptic level must not be higher than 10
-6, that is: aseptic level must not be higher than 1,000,000/, F
0Value is greater than 8.
Preferably, (or claim: low dose of independent packaging), the volume scope of the container of described single dose independent packaging is 0.1～5.0 milliliter/to the independent packaging of the ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent employing single dose.
The eye drop finished product adopts the plastics independent packaging of disposable single dose usually.
Preferably, the ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent, the medicine liquid volume scope that adopts the single dose independent packaging are 0.01～5.0 milliliter/.
The eye drop finished product should meet that " Chinese pharmacopoeia is to the requirement under the eye drop item, and should meet country's other correlated quality requirement to ZHENZHU MINGMU DIYANYE.
After each single dose individual packets is contained in and uses at every turn, no longer reuse.Can be made into one or more groups single dose eye drop finished product during production.
The beneficial effect that the present invention is compared with prior art had is:
One, eye drop of the present invention bacteriostatic agent has not been avoided because the potential danger that antibacterial causes and to the toxic and side effects of eyes uses product of the present invention safer, reliable.
Two, the present invention adopts sterile working's filling process production or sterilization process production, has guaranteed the aseptic requirement of product.
Three, the present invention adopts the single dose independent packaging, discards after the disposable use, and medicinal liquid can not be secondary polluted, and the integrity of other single dose independent packaging is unaffected.
Four, product of the present invention bacteriostatic agent has not been saved the cost that multiple-unit container must add adjuvants such as antibacterial.
The specific embodiment
Below the present invention is further illustrated by specific embodiment.
Embodiment one
Prescription:
Its preparation method:
A. precision is measured the 20mL Margarita liquid, precision takes by weighing 8.9g sodium chloride, adds the dissolving of 200mL water for injection; The 1.0g Borneolum Syntheticum is dissolved in 5mL 95% ethanol, adds in the above-mentioned solution, after stirring, be settled to 1000mL, get medicinal liquid with water for injection.
B. above-mentioned medicinal liquid is through 0.45 μ m filtering with microporous membrane 1 time, under hundred grades of environment, again through 0.22 μ m filtering with microporous membrane 2 times.
C. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 0.4mL seals to 1mL unit dose package plastic containers, gets product.
Embodiment two
Prescription:
Its preparation method:
A. precision is measured the 20mL Margarita liquid, precision takes by weighing 7.24g sodium dihydrogen phosphate, 0.94g sodium hydrogen phosphate, 4.5g sodium chloride, adds the dissolving of 200mL water for injection; The 1.0g Borneolum Syntheticum is dissolved in 5mL95% ethanol, adds in the above-mentioned solution, after stirring, be settled to 1000mL, get medicinal liquid with water for injection.
B. with the medicinal liquid of above-mentioned preparation, through 0.45 μ m filtering with microporous membrane 1 time, again through 0.22 μ m filtering with microporous membrane 1 time.
C. filtered liquid medicine adopts autoclaving, sterilizes 8 minutes cooling down in 121 ℃.
D. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 0.5mL seals to 1mL unit dose package plastic containers, gets product.
Embodiment three
Prescription:
Its preparation method:
A. precision is measured the 20mL Margarita liquid, precision takes by weighing 12.0g boric acid, 0.6g Borax, 5.8g glycerol, 1.0g hyaluronic acid sodium, adds the dissolving of 200mL water for injection; The 1.0g Borneolum Syntheticum is dissolved in 5mL 95% ethanol, adds in the above-mentioned solution, after stirring, be settled to 1000mL, get medicinal liquid with water for injection.
B. above-mentioned medicinal liquid is through 0.45 μ m filtering with microporous membrane 1 time, under hundred grades of environment, again through 0.22 μ m filtering with microporous membrane 2 times.
C. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 0.6mL seals to 1mL unit dose package plastic containers, gets product.
Embodiment four
Prescription:
Its preparation method:
A. accurate 1.0g Borneolum Syntheticum is dissolved in 5mL 95% ethanol, adds the dissolving of 200mL water for injection; Precision is measured the 20mL Margarita liquid, precision takes by weighing 5.6g sodium dihydrogen phosphate, 2.8g sodium hydrogen phosphate, 13.5g glycerol, 1.0g sodium sulfite, 0.1g disodiumedetate, add in the above-mentioned solution, after stirring, be settled to 1000mL, get medicinal liquid with water for injection.
B. above-mentioned medicinal liquid is through 0.45 μ m filtering with microporous membrane 1 time, under hundred grades of environment, again through 0.22 μ m filtering with microporous membrane 2 times.
C. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 1.0mL seals to 2mL unit dose package plastic containers, gets product.
Embodiment five
Prescription:
Its preparation method:
A. precision takes by weighing the 1.5g hyaluronic acid sodium, adds 300mL water for injection and makes it dissolving, and constant temperature stirs for 50～70 ℃ and made it reach sufficient swelling in 14 hours, cooling, and it is standby to get solution 1; Precision takes by weighing 1.0
The g Borneolum Syntheticum is dissolved in 5mL 95% ethanol, adds the dissolving of 200mL water for injection, and precision is measured the 20mL Margarita liquid, precision takes by weighing 12.0g boric acid, 0.6g Borax, 2.0g sodium chloride, joins in the Borneolum Syntheticum solution, stirs, and it is standby to get solution 2; Solution 1 and solution 2 are mixed, after stirring, be settled to 1000mL, get medicinal liquid with water for injection.
B. above-mentioned medicinal liquid is through 0.45 μ m filtering with microporous membrane 1 time, under hundred grades of environment, again through 0.22 μ m filtering with microporous membrane 2 times.
C. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 0.4mL seals to 1mL unit dose package plastic containers, gets product.
Embodiment six
Prescription:
Its preparation method:
A. precision takes by weighing the 1.0g Borneolum Syntheticum and is dissolved in 5mL 95% ethanol, add the dissolving of 200mL water for injection, precision is measured the 20mL Margarita liquid, precision takes by weighing 6.43g sodium dihydrogen phosphate, 1.89g sodium hydrogen phosphate, 13.0g glycerol, add in the above-mentioned solution, after stirring, be settled to 1000mL with water for injection, get medicinal liquid.
B. with the medicinal liquid of above-mentioned preparation, through 0.45 μ m filtering with microporous membrane 1 time, again through 0.22 μ m filtering with microporous membrane 1 time.
C. filtered liquid medicine adopts autoclaving, sterilizes 8 minutes cooling down in 121 ℃.
D. medicinal liquid after the assay was approved, under hundred grades of environment, the above-mentioned medicinal liquid of fill 0.8mL seals to 1mL unit dose package plastic containers, gets product.
Prescription is example with 1000mL all in the embodiment of the invention, can be with reference to the corresponding increase amount of preparation of prescription ratio in the actual industrial production.
Claims (6)
1, the ZHENZHU MINGMU DIYANYE of bacteriostatic agent not is characterized in that it comprises following component:
Margarita liquid 18.0～22.0mL
Borneolum Syntheticum 0.9～1.1g
Isotonic agent 0.1～50g
Add the injection water and be settled to 1000mL
Described isotonic agent is that in sodium chloride, potassium chloride, boric acid, Borax, sodium sulfate, potassium sulfate, Chile saltpeter, potassium nitrate, sodium acetate, mannitol, glycerol, propylene glycol, the glucose one or more are composite.
2, the ZHENZHU MINGMU DIYANYE of not bacteriostatic agent as claimed in claim 1 is characterized in that it also comprises one or more assembly in pH regulator agent, stabilizing agent, thickening agent, the solubilizing agent:
Described pH regulator agent is: 0.1～50g
Described stabilizing agent is: 0.01～5g
Described thickening agent is: 0.01～10g
Described solubilizing agent is: 1.0～10g
Described pH regulator agent is that in sodium dihydrogen phosphate, sodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, boric acid, Borax, acetic acid, sodium acetate, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide, hydrochloric acid, the phosphoric acid one or more are composite;
Described stabilizing agent is that in sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium nitrite, sodium thiosulfate, ascorbic acid (vitamin C), thiourea, ascorbyl stearate, dibutyl hydroxy toluene, cysteine, tocopherol acetas, dichloro isocyanide, disodiumedetate (EDTA-2Na, disodium edetate), calcio-disodium edetate, dimercaptopropanol, BAL, glycerol, mannitol, the butylated hydroxyanisol one or more are composite;
Described thickening agent is that in hyaluronate sodium, chondroitin sulfate, methylcellulose, hydroxy methocel, hydroxypropyl methylcellulose, cellulose, polyvidone, polyvinylpyrrolidone, polyvinyl alcohol, chitosan, beta cyclodextrin, carbomer, glucosamine polymer, glycerol, propylene glycol, Polyethylene Glycol, the polyvinyl alcohol one or more are composite.
Described solubilizing agent is ethanol, tween, glycerol, propylene glycol, Polyethylene Glycol.
3, as the preparation method of the ZHENZHU MINGMU DIYANYE of claim 1 or the described not bacteriostatic agent of claim 2, it is characterized in that it may further comprise the steps:
A. precision is measured Margarita liquid 18.0～22.0mL, precision takes by weighing Borneolum Syntheticum 0.9～1.1g, isotonic agent 0.1～50g, pH regulator agent 0.1～50g, stabilizing agent 0.01～5g, solubilizing agent 1.0～10.0g, 1/5～1/4 dissolving that adds the water for injection total amount, mix, transfer the pH scope to be: 4.5～7.0, be settled to 1000mL with water for injection, get medicinal liquid;
B. under hundred grades of environment, with step a gained medicinal liquid through 0.22～0.45 μ m filtering with microporous membrane 1 to 5 time;
C. testing sequence b gained medicinal liquid, qualified after, under hundred grades of environment, liquid drug is sealed to the unit dose package container, gets product.
4, as the preparation method of the ZHENZHU MINGMU DIYANYE of claim 1 or the described not bacteriostatic agent of claim 2, it is characterized in that it may further comprise the steps:
A. precision is measured Margarita liquid 18.0～22.0mL, precision takes by weighing Borneolum Syntheticum 0.9～1.1g, isotonic agent 0.1～50g, pH regulator agent 0.1～50g, stabilizing agent 0.01～5g, solubilizing agent 1.0～10.0g, 1/5～1/4 dissolving that adds the water for injection total amount, mix, transfer the pH scope to be: 4.5～7.0, be settled to 1000mL with water for injection, get medicinal liquid;
B. under hundred grades of environment, with step a gained medicinal liquid through 0.22～0.45 μ m filtering with microporous membrane 1 to 5 time;
C. with step b gained medicinal liquid pressure sterilizing;
D. testing sequence c gained medicinal liquid, qualified after, under hundred grades of environment, liquid drug is sealed to the unit dose package container, gets product.
5, the ZHENZHU MINGMU DIYANYE of not bacteriostatic agent as claimed in claim 1 or 2, it is characterized in that: the ZHENZHU MINGMU DIYANYE of described not bacteriostatic agent adopts the single dose independent packaging, and the volume scope of the container of described single dose independent packaging is 0.1～5.0 milliliter/.
6, the ZHENZHU MINGMU DIYANYE of not bacteriostatic agent as claimed in claim 5 is characterized in that: the medicine liquid volume scope of described single dose independent packaging is 0.01～5.0 milliliter/.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100736014A CN101455683A (en) | 2009-01-06 | 2009-01-06 | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100736014A CN101455683A (en) | 2009-01-06 | 2009-01-06 | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101455683A true CN101455683A (en) | 2009-06-17 |
Family
ID=40766982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100736014A Pending CN101455683A (en) | 2009-01-06 | 2009-01-06 | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101455683A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623003A (en) * | 2013-09-09 | 2014-03-12 | 苏州工业园区天龙制药有限公司 | Pearl eye drops for improving eyesight and preparation method thereof |
| CN104173384A (en) * | 2014-09-12 | 2014-12-03 | 江西珍视明药业有限公司 | Non-terminally-sterilized sterile four nacre-borneol-boric acid-borax eyedrop and preparation method thereof |
| CN105769920A (en) * | 2014-12-25 | 2016-07-20 | 苏州太湖美药业有限公司 | Pearl clear-sighted eye drops and preparation method |
| CN106344602A (en) * | 2016-08-29 | 2017-01-25 | 安徽艾珂尔制药有限公司 | Naphazoline hydrochloride, chlorphenamine maleate and vitamin B12 eyedrop compound preparation and preparation method thereof |
-
2009
- 2009-01-06 CN CNA2009100736014A patent/CN101455683A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623003A (en) * | 2013-09-09 | 2014-03-12 | 苏州工业园区天龙制药有限公司 | Pearl eye drops for improving eyesight and preparation method thereof |
| CN103623003B (en) * | 2013-09-09 | 2016-03-23 | 苏州工业园区天龙制药有限公司 | A kind of ZHENZHU MINGMU DIYANYE and preparation method thereof |
| CN104173384A (en) * | 2014-09-12 | 2014-12-03 | 江西珍视明药业有限公司 | Non-terminally-sterilized sterile four nacre-borneol-boric acid-borax eyedrop and preparation method thereof |
| CN104173384B (en) * | 2014-09-12 | 2015-12-30 | 江西珍视明药业有限公司 | A kind of aseptic SIWEIZHENCENGBINGPENG DIYANYE of non-final sterilizing and preparation method |
| CN105769920A (en) * | 2014-12-25 | 2016-07-20 | 苏州太湖美药业有限公司 | Pearl clear-sighted eye drops and preparation method |
| CN106344602A (en) * | 2016-08-29 | 2017-01-25 | 安徽艾珂尔制药有限公司 | Naphazoline hydrochloride, chlorphenamine maleate and vitamin B12 eyedrop compound preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461777A (en) | Disposable levofloxacin hydrochloride eye drops without bacteriostatic agent and preparation method thereof | |
| CN101461779A (en) | Disposable ofloxacin eye drops without bacteriostatic agent and preparation method thereof | |
| CN101455633A (en) | Disposable levofloxacin lactate eye drops without bacteria inhibitor and preparation method thereof | |
| US9173945B2 (en) | Ophthalmological aqueous composition | |
| RU2621144C2 (en) | Pharmaceutical form of gemcitabine of large volume for infusion and kit containing formulations | |
| CN101461776A (en) | Sodium hyaluronate eye drops without bacteriostatic agent and preparation method thereof | |
| NO335022B1 (en) | Process for preparing a ciclesonide containing sterile aqueous suspension | |
| CN101474146A (en) | Timolol maleate eye drops without bacteriostatic agent and preparation method thereof | |
| CN101455683A (en) | Pearls eyesight-improving eye drops without bacteria inhibitor and preparation method thereof | |
| CN101461778A (en) | Disposable levofloxacin hydrochloride eye drops without bacteriostatic agent and preparation method thereof | |
| CN101455684A (en) | Zhenshiming eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455635A (en) | Cromoglyn sodium eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455636A (en) | Naphazoline hydrochloride, chlorphenamine maleate and vitamin B12 eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455634A (en) | Composite aspartate, vitamin B6 and dipotassium glycyrrhetate eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455639A (en) | Acyclovir eye drops without bacteria inhibitor and preparation method thereof | |
| CN101461781A (en) | Gernebcin eye drops without bacteriostatic agent and preparation method thereof | |
| CN103432069A (en) | Ofloxacin eye drop without bacteriostatic agent and preparation method of ofloxacin eye drop | |
| CN104127377A (en) | Diclofenac sodium eye drops containing no antimicrobial agent and preparation method thereof | |
| US9789080B2 (en) | Ophthalmic formulations of mycophenolic acid | |
| CN101444481A (en) | Tropicamide eye drops without bacteria inhibitor and the preparation method thereof | |
| CN101461775A (en) | Chloromycetin eyedrops without bacteriostatic agent and preparation method thereof | |
| CN101455638A (en) | Ribavirin eye drops without bacteria inhibitor and preparation method thereof | |
| CN101455637A (en) | Bendazac lysine eye drops without bacteria inhibitor and preparation method thereof | |
| CN101461780A (en) | Carteolol hydrochloride eye drops without bacteriostatic agent and preparation method thereof | |
| US20220000766A1 (en) | Parenteral nutrition containing trace elements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090617 |